These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19155770)

  • 1. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
    Capetti AF; Piconi S; Landonio S; Rizzardini G; Perno CF
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):233-4. PubMed ID: 19155770
    [No Abstract]   [Full Text] [Related]  

  • 2. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
    Arazo Garcés P; Omiste Sanvicente T
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 7. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients.
    Casado JL; Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Montero M; Mena A; Palacios R; Lopez JC; Vergas J; Galindo MJ; Cabello A; Deltoro MG; Diaz De Santiago A;
    Int J STD AIDS; 2020 Apr; 31(5):467-473. PubMed ID: 32138618
    [No Abstract]   [Full Text] [Related]  

  • 9. XVI International AIDS Conference: Part 2.
    Boyle BA; Cohen CJ; Moyle GJ; Elion R; Sax PE; Frank I
    AIDS Read; 2006 Nov; 16(11):581-4, 591-2. PubMed ID: 17152645
    [No Abstract]   [Full Text] [Related]  

  • 10. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
    Grant P; Zolopa A
    J HIV Ther; 2008 Jun; 13(2):36-9. PubMed ID: 18953272
    [No Abstract]   [Full Text] [Related]  

  • 14. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
    Moreno A; Quereda C; Montes M; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Dronda F; Bárcena R; Del Campo S; Moreno S
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e47-9. PubMed ID: 23095936
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical pharmacology of antiretrovirals in development.
    Winston A; Mallon PW; Boffito M
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.